357 related articles for article (PubMed ID: 22858176)
1. Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study.
Brennan BJ; Xu ZX; Grippo JF
Clin Ther; 2012 Sep; 34(9):1883-91. PubMed ID: 22858176
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C.
Brennan BJ; Morcos PN; Wang K; Blotner SD; Morrison R; Hagedorn CH; Marbury TC; Sulkowski M; Grippo JF
Aliment Pharmacol Ther; 2012 May; 35(10):1209-20. PubMed ID: 22469033
[TBL] [Abstract][Full Text] [Related]
3. A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects.
Zheng L; Li MP; Gou ZP; Wang Y; Xu N; Cai YM; Luo H
Br J Clin Pharmacol; 2015 Apr; 79(4):650-9. PubMed ID: 25297637
[TBL] [Abstract][Full Text] [Related]
4. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
Talpaz M; Rakhit A; Rittweger K; O'Brien S; Cortes J; Fettner S; Hooftman L; Kantarjian H
Clin Cancer Res; 2005 Sep; 11(17):6247-55. PubMed ID: 16144928
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Ginsberg M; Rittweger K; Vuky J; Yu R; Fettner S; Hooftman L
J Clin Oncol; 2001 Mar; 19(5):1312-9. PubMed ID: 11230473
[TBL] [Abstract][Full Text] [Related]
7. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).
Reddy KR
Semin Liver Dis; 2004; 24 Suppl 2():33-8. PubMed ID: 15346244
[TBL] [Abstract][Full Text] [Related]
8. Population PK-PD Model of Pegylated Interferon Alfa-2a in Healthy Korean Men.
Jung YS; Chae D; Park K
J Pharm Sci; 2018 Dec; 107(12):3171-3178. PubMed ID: 30179597
[TBL] [Abstract][Full Text] [Related]
9. Peginterferon alfa-2a: a review of approved and investigational uses.
Matthews SJ; McCoy C
Clin Ther; 2004 Jul; 26(7):991-1025. PubMed ID: 15336466
[TBL] [Abstract][Full Text] [Related]
10. Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.
Zeuzem S; Yoshida EM; Benhamou Y; Pianko S; Bain VG; Shouval D; Flisiak R; Rehak V; Grigorescu M; Kaita K; Cronin PW; Pulkstenis E; Subramanian GM; McHutchison JG
Hepatology; 2008 Aug; 48(2):407-17. PubMed ID: 18666223
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of peginterferons.
Zeuzem S; Welsch C; Herrmann E
Semin Liver Dis; 2003; 23 Suppl 1():23-8. PubMed ID: 12934165
[TBL] [Abstract][Full Text] [Related]
12. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.
Rustgi VK; Lee WM; Lawitz E; Gordon SC; Afdhal N; Poordad F; Bonkovsky HL; Bengtsson L; Chandorkar G; Harding M; McNair L; Aalyson M; Alam J; Kauffman R; Gharakhanian S; McHutchison JG;
Hepatology; 2009 Dec; 50(6):1719-26. PubMed ID: 19852040
[TBL] [Abstract][Full Text] [Related]
13. Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy.
Sulkowski M; Wright T; Rossi S; Arora S; Lamb M; Wang K; Gries JM; Yalamanchili S
Clin Pharmacol Ther; 2005 Mar; 77(3):214-24. PubMed ID: 15735615
[TBL] [Abstract][Full Text] [Related]
14. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.
Glue P; Fang JW; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S
Clin Pharmacol Ther; 2000 Nov; 68(5):556-67. PubMed ID: 11103758
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS).
Bressler B; Wang K; Grippo JF; Heathcote EJ
Br J Clin Pharmacol; 2009 Mar; 67(3):280-7. PubMed ID: 19523011
[TBL] [Abstract][Full Text] [Related]
16. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
McHutchison J; Sulkowski M
J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
[TBL] [Abstract][Full Text] [Related]
17. Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected patients with genotype 1: results of a retrospective evaluation.
Zopf S; Herold C; Hahn EG; Ganslmayer M
Scand J Gastroenterol; 2009; 44(4):486-90. PubMed ID: 19117241
[TBL] [Abstract][Full Text] [Related]
18. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects.
Nieforth KA; Nadeau R; Patel IH; Mould D
Clin Pharmacol Ther; 1996 Jun; 59(6):636-46. PubMed ID: 8681488
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.
Asahina Y; Izumi N; Umeda N; Hosokawa T; Ueda K; Doi F; Tsuchiya K; Nakanishi H; Matsunaga K; Kitamura T; Kurosaki M; Uchihara M; Higaki M; Miyake S
J Viral Hepat; 2007 Jun; 14(6):396-403. PubMed ID: 17501760
[TBL] [Abstract][Full Text] [Related]
20. Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity.
Brennan BJ; Xu ZX; Grippo JF
Br J Clin Pharmacol; 2013 Feb; 75(2):497-506. PubMed ID: 22765278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
